Calliditas Partner STADA Receives European Commission Decision For Full Approval Of Kinpeygo For The Treatment Of IgA Nephropathy
Portfolio Pulse from Benzinga Newsdesk
Calliditas Therapeutics announced that the European Commission has granted full marketing authorization for Kinpeygo for the treatment of adults with primary IgA nephropathy. This approval expands the patient population eligible for treatment.
July 26, 2024 | 3:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Calliditas Therapeutics received full marketing authorization from the European Commission for Kinpeygo, expanding its use for primary IgA nephropathy. This approval broadens the eligible patient population, potentially increasing market reach and revenue.
The full marketing authorization from the European Commission significantly broadens the patient population eligible for Kinpeygo, which is likely to increase the drug's market reach and revenue potential. This is a positive development for Calliditas Therapeutics.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100